"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA approves selumetinib (Koselugo) for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

FDA approves selumetinib (Koselugo) for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

13 Apr 2020 8:31 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved selumetinib (Koselugo; AstraZeneca) for neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurocfibromas (PN). Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software